Recombinant Vaccinia virus Protein L1 (MVA080R, ACAM3000_MVA_080)

Basic Research Questions

• What is the structure and function of L1 protein in vaccinia virus?

  L1 (also called L1R) is a 250-residue myristoylated transmembrane protein expressed on the surface of the intracellular mature virion (IMV) form of vaccinia virus. The protein consists of a 185-residue disulfide-bonded ectodomain and a C-terminal hydrophobic segment embedded in the viral membrane. Structurally, L1's N-terminal region folds as a bundle of helices surrounding a pair of beta strands, with a hydrophobic cavity located adjacent to its N-terminus that can shield the myristate moiety . The protein is essential for both virion assembly and cellular entry. Notably, L1 is highly conserved throughout the poxvirus family and is nearly identical in vaccinia virus and variola virus (which causes smallpox) . Functionally, L1 serves as a receptor binding protein (RBP) that binds to cell surfaces independently of glycosaminoglycans (GAGs) .

• Why is L1 protein significant as a vaccine target?

  L1 is a potent target for neutralizing antibodies and is critical for virus entry and infection. Studies have shown that monoclonal antibodies against L1 exhibit potent virus-neutralizing activity in plaque reduction assays and can diminish vaccinia virus-induced cell-cell fusion at low pH . Due to these characteristics, L1 has become a key component of several subunit vaccine candidates developed for protection against orthopoxvirus diseases . The protein's high conservation across the poxvirus family makes it particularly valuable, as vaccines targeting L1 may provide cross-protection against various poxviruses, including the deadly variola virus. L1 has demonstrated efficacy in both multi-gene DNA vaccines and multicomponent protein vaccines in animal models, blocking lethal viral challenge in mice and non-human primates .

• How can researchers verify the proper folding of recombinantly expressed L1 protein?

  Proper folding of recombinant L1 protein can be verified using immunological methods that test binding to known anti-L1 antibodies. One established approach is to use an enzyme-linked immunosorbent assay (ELISA) with the following methodology:

  1. Coat ELISA plates with a known anti-poxvirus L1 antibody (such as 7D11) at 10 μg/mL and incubate overnight at 4°C

  2. Block plates with 5% milk in PBS

  3. Add L1R preparations at 100 μg/mL

  4. Detect bound L1R using anti-His horseradish peroxidase (if the recombinant protein has a His-tag)

  5. Develop with HRP substrate (such as ABTS) and read absorbance at 405 nm

  Strong binding to a characterized antibody like 7D11 indicates that the protein is intact and properly folded . Additional structural verification can be performed through circular dichroism spectroscopy or limited proteolysis to assess secondary structure elements and protein stability.

• What are the basic expression systems for producing recombinant L1 protein?

  Recombinant L1 protein can be expressed in various systems, with E. coli being the most commonly documented. The typical methodology for E. coli expression includes:

  1. Cloning the L1R gene (commonly residues 1-185) into an expression vector like pET21b with a C-terminal hexahistidine tag

  2. Transforming the plasmid into BL21(DE3) or similar expression strains

  3. Inducing protein expression with IPTG when cultures reach appropriate density

  4. Recovering the protein from inclusion bodies through solubilization and refolding

  The typical yield is approximately 2 mg of purified protein per liter of bacterial culture . Alternative expression systems include insect cells using baculovirus vectors or mammalian cell expression, which may better preserve post-translational modifications like myristoylation but often yield lower protein amounts compared to bacterial systems.